Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology

• Published in: Bioorganic chemistry Vol. 96; p. 103616
• Main Authors: El Ashry, El Sayed Helmy, Awad, Laila Fathy, Teleb, Mohamed, Ibrahim, Nihal Ahmed, Abu-Serie, Marwa M., Abd Al Moaty, Mohamed Nabil
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2020
• Subjects: Anticancer; Cell Line, Tumor; Dimroth rearrangement; Drug Design; Drug Screening Assays, Antitumor; Humans; Matrix Metalloproteinase 10 - metabolism; Matrix Metalloproteinase 13 - metabolism; Matrix Metalloproteinase Inhibitors - chemistry; Matrix Metalloproteinase Inhibitors - pharmacology; MMP-10/13; Molecular Docking Simulation; Neoplasms - drug therapy; Neoplasms - metabolism; Polypharmacology; Pyridines - chemistry; Pyridines - pharmacology; Pyrimidine; Structure-Activity Relationship; Triazoles - chemistry; Triazoles - pharmacology; Triazolopyrimidine; MMP-10/13; Triazolopyrimidine; Dimroth rearrangement; Polypharmacology; Anticancer; Pyrimidine
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2020.103616

[Display omitted] •Novel hydrazones 6–10 were cyclized to isomeric triazolo[4,3-a]pyrimidines 12–19.•5-Oxo-1,2,4-triazolo[4,3-a]pyrimidines exhibited higher MMP-10/13 inhibition than their regioisomers.•Inactive triazolopyrimidines were rearranged to the potent Dimroth products.•The most active MMP-10 inhibitor 16 (IC50 = 24 nM) was selective over MMP-13,-9 and-7.•MMP-10/13 inhibitors 16 and 18 exhibited anticancer activities superior to quercetin. Recently, interest in matrix metalloproteinases (MMPs) -10 and -13 has been revitalized with the growing knowledge on their relevance within the MMPs network and significance of their inhibition for treatment of various diseases like arthritis, cancer, atherosclerosis and Alzheimer. Within this approach, dual MMP-10/13 inhibition was disclosed as new approach for targeted polypharmacology. While several efficient MMP-13 inhibitors are known, very few potent and selective MMP-10 inhibitors were reported. This study describes the design, synthesis and optimization of novel MMP-10/13 inhibitors with enhanced MMP-10 potency and selectivity towards polypharmacology. Starting with a lead fused pyrimidine-based MMP-13 inhibitor with weak MMP-10 inhibition, a structure-based design of pyrimidine and fused pyrimidine scaffolds was rationalized to enhance activity against MMP-10 in parallel with MMP-13. Firstly, a series of 6-methyl pyrimidin-4-one hydrazones 6–10 was synthesized via conventional and ultrasonic-assisted methods, then evaluated for MMP-10/13 inhibition. The most active derivative 9 exhibited acceptable dual potency with 7-fold selectivity for MMP-10 (IC50 = 53 nM) over MMP-13. Such hydrazones were then cyclized to the corresponding isomeric 1,2,4-triazolo[4,3-a]pyrimidines 12–19. Their MMP-10/13 inhibition assay revealed, in most cases, superior dual activities with general MMP-10 selectivity compared to the corresponding precursors 6–10. In addition, a clear structure activity relationship trend was deduced within the identified regioisomers, where the 5-oxo-1,2,4-triazolo[4,3-a]pyrimidine derivatives 15 and 16 were far more active against MMP-10/13 than their regioisomers 12 and 13. Remarkably, the p-bromophenyl derivative 16 exhibited the highest MMP-10 inhibition (IC50 = 24 nM), whereas the p-methoxy derivative 18 was the most potent MMP-13 inhibitor (IC50 = 294 nM). Moreover, 16 exhibited 19-fold selectivity for MMP-10 over MMP-13, 10-fold over MMP-9, and 29-fold over MMP-7. Docking studies were performed to provide reasonable explanation for structure-activity relationships and isoform selectivity. 16 and 18 were then evaluated for their anticancer activities against three human cancers to assess their therapeutic potential at cellular level via MTT assay. Both compounds exhibited superior anticancer activities compared to quercetin. Their in silico ligand efficiency metrics, physicochemical properties and ADME parameters were drug-like. Guided by such findings that point to 16 as the most promising compound in this study, further structure optimization was carried out via photoirradiation-mediated Dimroth rearrangement of the inactive triazolopyrimidine 13 to its potent regioisomer 16.